Vanda Sets $240 Million-Plus 2026 Revenue Goal, Plans Q4 BYSANTI Launch
Photo: TokenPost
Vanda Pharmaceuticals Inc. said it is targeting more than $240 million in revenue for 2026 and plans to launch BYSANTI in the fourth quarter. Management linked the third-quarter results to continued momentum from Fanapt and an early contribution from NEREUS, whose commercial launch had recently begun. HETLIOZ and PONVORY also contributed to revenue. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
